OPGN - OpGen Inc Stock Price, Fair Value and News

0.61USD+0.01 (+1.67%)Market Closed

Market Summary

USD0.61+0.01

Market Closed

1.67%

OPGN Stock Price

View Fullscreen

OPGN RSI Chart

OPGN Valuation

Market Cap

6.1M

Price/Earnings (Trailing)

-0.24

Price/Sales (Trailing)

2.05

EV/EBITDA

-0.27

Price/Free Cashflow

-0.35

OPGN Price/Sales (Trailing)

OPGN Profitability

EBT Margin

-852.12%

Return on Equity

-977.39%

Return on Assets

-144.26%

Free Cashflow Yield

-282.82%

OPGN Fundamentals

OPGN Revenue

Revenue (TTM)

3.1M

Rev. Growth (Yr)

55.78%

Rev. Growth (Qtr)

-5.04%

OPGN Earnings

Earnings (TTM)

-26.2M

Earnings Growth (Yr)

71.19%

Earnings Growth (Qtr)

30.28%

Breaking Down OPGN Revenue

Last 7 days

-14.1%

Last 30 days

24.5%

Last 90 days

144%

Trailing 12 Months

-44.5%

How does OPGN drawdown profile look like?

OPGN Financial Health

Current Ratio

0.28

OPGN Investor Care

Shares Dilution (1Y)

272.95%

Diluted EPS (TTM)

-6.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.1M	2.8M	3.1M	0
2022	3.9M	4.1M	3.3M	2.6M
2021	4.4M	4.1M	4.2M	4.3M
2020	3.1M	3.3M	3.7M	4.2M
2019	3.1M	3.3M	3.4M	3.5M
2018	1.0M	1.7M	2.3M	2.9M
2017	3.7M	3.2M	3.2M	357.2K
2016	3.8M	4.6M	4.3M	4.0M
2015	3.5M	2.8M	3.0M	3.2M
2014	0	0	0	4.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of OpGen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	ben-tzvi avraham	acquired	-	-	100,000	-
Apr 11, 2024	mcmurdo matthew charles	acquired	-	-	100,000	-
Apr 11, 2024	lazar david e.	acquired	-	-	100,000	chief executive officer
Apr 11, 2024	natan david	acquired	-	-	100,000	-
Jun 07, 2023	crovetto mario	acquired	-	-	1,500	-
Jun 07, 2023	schlaeppi yvonne	acquired	-	-	1,500	-
Jun 07, 2023	fernandes prabhavathi	acquired	-	-	1,500	-
Jun 07, 2023	rhodes william e.	acquired	-	-	1,500	-
Jun 07, 2023	elsey r don	acquired	-	-	1,500	-
Mar 31, 2023	bacher johannes	acquired	-	-	6,434	chief operating officer

Which funds bought or sold OPGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	45.16	7,674	22,376	-%
Feb 26, 2024	Virtu Financial LLC	new	-	17,000	17,000	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-	-	-%
Feb 14, 2024	Arete Wealth Advisors, LLC	sold off	-100	-6,009	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	5,083	5,083	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-4,083	-	-%
Feb 14, 2024	BNP PARIBAS FINANCIAL MARKETS	new	-	-	-	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	15,282	15,282	-%
Feb 13, 2024	NewEdge Advisors, LLC	unchanged	-	1.00	21.00	-%

Are Funds Buying or Selling OPGN?

Are funds buying OPGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OPGN

No. of Funds

Unveiling OpGen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	lazar david e.	19.9%	2,390,861	SC 13D/A
Apr 01, 2024	lazar david e.	19.9%	2,390,861	SC 13D
May 11, 2020	curetis n.v. in liquidation	0.00%	0	SC 13D/A
Apr 22, 2020	curetis n.v. in liquidation	11.65%	1,711,555	SC 13D/A
Apr 13, 2020	curetis n.v. in liquidation	13.8%	2,028,208	SC 13D
Feb 10, 2020	cvi investments, inc.	3.5%	2e+05	SC 13G/A
Jan 06, 2020	sabby management, llc	12.%	0	SC 13G/A
Nov 27, 2019	merck global health innovation fund, llc	0.44%	24,597	SC 13D/A
Nov 01, 2019	cvi investments, inc.	5.8%	2e+05	SC 13G
Nov 01, 2019	armistice capital, llc	4.99%	172,631	SC 13G

Recent SEC filings of OpGen Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	8-K	Current Report
Apr 16, 2024	PRE 14A	PRE 14A
Apr 15, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	SC 13D/A	13D - Major Acquisition
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	3	Insider Trading

Peers (Alternatives to OpGen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.1B	-6.98%	-6.26%	31.91	4.55	-8.12%	-17.45%
BDX	67.4B	19.5B	-2.95%	-9.93%	53.63	3.46	4.02%	-22.04%
ALGN	22.6B	3.9B	-4.96%	-15.40%	50.88	5.86	3.42%	23.09%
BAX	20.1B	14.8B	-5.44%	-9.06%	7.58	1.36	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.25%	17.23%	32.29	2.63	4.97%	18.89%
HSIC	9.0B	12.3B	-5.97%	-15.68%	21.61	0.73	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.50%	-42.23%	-12.88	3.07	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.09%	-25.03%	-46.91	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-2.40%	13.34%	-563.48	9.33	33.86%	89.83%
PDCO	2.3B	6.6B	-5.10%	-3.56%	11.8	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-10.67%	-21.18%	-1.84	0.39	7.73%	-1066.14%
ANIK	378.4M	166.7M	0.43%	-6.80%	-4.58	2.27	6.67%	-456.34%
ANGO	245.1M	324.0M	10.27%	-31.54%	-1.27	0.76	-3.19%	-337.41%
APYX	47.5M	52.3M	-23.89%	-53.56%	-2.54	0.91	17.61%	19.28%
AEMD	3.7M	3.7M	-12.80%	240.48%	-0.31	1	5.77%	8.23%

OpGen Inc News

Latest updates

OpGen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-5.0%	699,022	736,137	913,444	721,630	448,713	967,205	469,745	1,425,568	1,239,132	811,615	829,716	1,352,358	1,056,765	1,188,385	616,933	820,674	648,220	1,009,543	1,020,177	758,959	552,221
Costs and Expenses	-27.6%	4,264,647	5,892,493	5,983,555	10,657,508	13,962,011	6,239,410	6,315,485	7,212,289	6,325,718	6,950,126	7,090,934	7,382,575	7,232,727	7,706,199	4,611,419	3,323,598	4,073,648	3,590,470	4,782,143	4,437,208	3,782,419
S&GA Expenses	-71.0%	336,184	1,160,200	1,026,087	1,092,379	1,031,496	1,169,349	1,051,432	1,007,885	1,003,577	802,549	899,252	835,112	932,671	1,044,032	282,277	321,966	376,955	393,567	372,233	414,176	361,310
R&D Expenses	-13.5%	1,201,865	1,388,792	1,812,831	1,552,125	2,031,113	2,273,756	2,316,441	2,855,295	2,382,303	2,859,590	2,813,491	3,334,586	2,433,553	2,979,025	1,217,556	1,051,833	1,139,369	1,153,584	1,776,382	1,856,126	1,286,300
EBITDA Margin	36.3%	-7.30	-11.46	-10.53	-12.42	-8.39	-4.53	-4.85	-6.33	-6.48	-7.21	-6.73	-4.83	-4.74	-	-	-	-	-	-	-	-
Interest Expenses	-42.0%	396,768	684,498	617,298	637,611	569,306	779,912	1,269,581	1,213,313	1,222,867	1,198,169	1,164,982	1,132,299	1,183,927	1,044,891	38,267	44,877	49,099	37,129	56,444	50,742	28,074
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	30.3%	-4,062,957	-5,827,323	-5,736,603	-10,535,120	-14,103,982	-5,840,415	-6,803,716	-6,768,036	-6,056,696	-7,086,561	-14,850,591	-6,977,914	-7,675,595	-7,475,638	-3,949,294	-2,517,893	-3,482,438	-2,593,011	-3,853,116	-3,732,376	-3,255,425
EBT Margin	33.6%	-8.52	-12.84	-11.87	-14.30	-10.12	-6.21	-6.77	-8.07	-8.26	-9.03	-8.35	-6.19	-5.87	-	-	-	-	-	-	-	-
Net Income	30.3%	-4,062,957	-5,827,323	-5,736,603	-10,535,120	-14,103,982	-5,840,415	-6,803,716	-6,811,864	-6,056,696	-7,086,561	-14,850,591	-7,110,317	-7,675,595	-7,475,638	-3,949,294	-2,517,893	-3,482,438	-2,593,011	-3,853,116	-3,732,376	-3,255,425
Net Income Margin	33.6%	-8.52	-12.84	-11.87	-14.30	-10.14	-6.22	-6.78	-8.08	-8.29	-9.07	-8.38	-6.22	-5.87	-	-	-	-	-	-	-	-
Free Cashflow	40.8%	-3,029,630	-5,119,903	-5,293,064	-4,399,060	-4,856,943	-6,704,354	-5,080,113	-3,947,728	-5,232,889	-8,465,461	-5,816,813	-7,066,264	-7,226,824	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-19.2%	18,135	22,435	26,511	25,813	32,959	48,809	64,259	71,667	62,289	68,562	75,156	49,751	44,705	46,290	19,764	10,422	6,430	8,932	12,091	8,950	9,223
Current Assets	-52.2%	3,455	7,229	10,740	10,655	13,392	20,209	33,493	39,743	29,780	35,070	42,774	16,888	14,959	16,827	17,145	6,667	2,005	4,575	7,486	5,783	6,039
Cash Equivalents	-91.0%	293	3,237	7,039	7,440	10,276	16,587	30,653	36,080	25,352	31,182	39,397	13,360	10,488	12,887	11,469	2,708	626	3,056	6,012	4,572	4,736
Inventory	-	-	-	-	-	-	-	-	-	-	-	1,417	1,486	2,975	2,898	437	473	468	567	499	544	530
Net PPE	-0.8%	3,821	3,850	3,667	3,458	3,055	3,209	3,722	4,012	4,290	4,223	3,650	3,259	3,371	3,587	103	131	202	198	248	1,222	1,150
Goodwill	-	-	-	-	-	-	6,885	7,317	7,453	7,606	7,791	7,694	8,025	8,058	7,651	601	601	601	601	601	601	601
Liabilities	-0.8%	15,458	15,575	17,334	18,238	19,021	21,448	30,088	30,449	28,990	28,826	29,124	28,560	27,626	27,562	5,681	6,128	7,987	7,105	7,752	5,642	5,193
Current Liabilities	0.5%	12,472	12,416	8,636	10,592	12,012	14,394	19,013	19,917	19,166	4,857	6,573	7,372	8,607	9,467	4,913	4,939	6,434	5,159	5,483	4,381	3,865
Short Term Borrowings	-100.0%	-	9,191	4,959	7,024	8,343	10,887	14,395	14,519	14,668	-	282	699	1,157	1,378	348	374	508	343	348	399	471
LT Debt, Current	-	9,200	-	-	7,024	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-61.0%	2,677	6,860	9,177	7,576	13,938	27,361	34,171	41,217	33,299	39,736	46,031	21,191	17,079	18,729	14,083	4,293	-	1,827	4,339	3,309	4,030
Retained Earnings	-1.4%	-288,451	-284,388	-278,561	-272,824	-262,289	-248,185	-242,345	-235,541	-228,729	-222,672	-215,586	-200,735	-193,625	-185,949	-178,474	-174,524	-172,007	-168,524	-165,931	-162,078	-158,346
Additional Paid-In Capital	-0.1%	291,706	291,935	288,326	281,167	1,800	276,206	275,949	276,150	260,245	260,028	259,766	219,129	208,892	204,154	192,410	178,780	170,449	170,190	170,104	165,396	162,330
Shares Outstanding	43.7%	10,014	6,968	5,496	2,900	2,383	2,329	2,324	2,323	1,769	1,695	1,474	1,254	956	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	25,338	-	-	-	86,778	-	-	-	35,998	-	-	-	6,934,767,000	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	38.4%	-2,927	-4,752	-4,962	-3,994	-4,753	-6,659	-5,041	-3,788	-5,131	-7,593	-4,965	-6,938	-7,225	-6,888	-2,344	-3,449	-2,231	-2,838	-2,985	-2,697	-2,817
Share Based Compensation	-246.6%	-229	157	211	224	228	257	242	210	217	262	190	161	42.00	34.00	80.00	98.00	91.00	86.00	98.00	204	207
Cashflow From Investing	72.3%	-101	-367	-330	-404	-102	-44.85	-38.71	-158	-101	-872	-850	-127	-1.40	1,267	-2,201	-2,459	-47.93	12.00	-7.24	-105	-37.45
Cashflow From Financing	-98.2%	28.00	1,504	4,744	1,011	-899	-6,829	-17.53	15,414	-167	-99.98	32,305	9,872	4,090	6,860	13,265	7,999	-155	-123	4,448	2,614	164

OPGN Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Total revenue	$ 699,022	$ 448,713	$ 2,348,601	$ 1,885,663
Operating expenses
Cost of products sold	618,796	1,886,191	1,925,566	2,824,577
Cost of services	73,174	17,239	405,582	63,450
Research and development	1,201,865	2,031,113	4,403,488	6,621,310
General and administrative	2,034,628	2,020,452	6,883,588	6,779,773
Sales and marketing	336,184	1,031,496	2,522,471	3,252,277
Goodwill impairment charge		6,975,520		6,975,520
Total operating expenses	4,264,647	13,962,011	16,140,695	26,516,907
Operating loss	(3,565,625)	(13,513,298)	(13,792,094)	(24,631,244)
Other (expense) income
Interest and other income	24,977	11,174	86,301	28,147
Interest expense	(396,768)	(569,306)	(1,698,564)	(2,618,799)
Foreign currency transaction (losses) gains	(135,930)	(51,547)	(288,326)	419,160
Change in fair value of derivative financial instruments	10,389	18,995	65,800	54,623
Total other expense	(497,332)	(590,684)	(1,834,789)	(2,116,869)
Loss before income taxes	(4,062,957)	(14,103,982)	(15,626,883)	(26,748,113)
Provision for income taxes
Net loss	(4,062,957)	(14,103,982)	(15,626,883)	(26,748,113)
Net loss available to common stockholders	$ (4,062,957)	$ (14,103,982)	$ (15,626,883)	$ (26,748,113)
Net loss per common share – basic (in Dollars per share)	$ (0.46)	$ (5.92)	$ (2.38)	$ (11.4)
Weighted average shares outstanding – basic (in Shares)	8,778,152	2,382,848	6,565,853	2,345,794
Net loss	$ (4,062,957)	$ (14,103,982)	$ (15,626,883)	$ (26,748,113)
Other comprehensive income (loss) – foreign currency translation	78,815	(536,758)	118,178	(2,247,749)
Comprehensive loss	(3,984,142)	(14,640,740)	(15,508,705)	(28,995,862)
Product sales
Revenue
Total revenue	558,965	359,112	1,409,534	1,614,435
Laboratory services
Revenue
Total revenue	47,135	31,016	112,810	94,515
Collaboration revenue
Revenue
Total revenue	$ 92,922	$ 58,585	$ 826,257	$ 176,713

OPGN Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 292,642	$ 7,440,030
Accounts receivable, net	422,725	514,372
Inventory, net	1,198,259	1,345,137
Prepaid expenses and other current assets	1,541,074	1,355,949
Total current assets	3,454,700	10,655,488
Property and equipment, net	3,820,829	3,457,531
Finance lease right-of-use assets, net	986	3,500
Operating lease right-of-use assets	1,915,049	1,459,413
Intangible assets, net	6,842,406	7,440,974
Strategic inventory	1,608,890	2,300,614
Other noncurrent assets	492,022	495,629
Total assets	18,134,882	25,813,149
Current liabilities
Current maturities of long-term debt	9,199,764	7,023,901
Accounts payable	904,559	420,821
Accrued compensation and benefits	381,807	1,097,654
Accrued liabilities	1,268,723	1,526,204
Deferred revenue	194,687	142,061
Short-term finance lease liabilities	1,121	3,364
Short-term operating lease liabilities	521,424	377,626
Total current liabilities	12,472,085	10,591,631
Long-term debt, net		4,850,686
Derivative liabilities	34,364	99,498
Long-term finance lease liabilities		280
Long-term operating lease liabilities	2,830,282	2,566,138
Other long-term liabilities	121,428	129,368
Total liabilities	15,458,159	18,237,601
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.01 par value; 100,000,000 shares authorized; 10,013,524 and 2,899,911 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	100,135	28,999
Additional paid-in capital	291,705,905	281,167,161
Accumulated deficit	(288,451,655)	(272,824,772)
Accumulated other comprehensive loss	(677,662)	(795,840)
Total stockholders’ equity	2,676,723	7,575,548
Total liabilities and stockholders’ equity	$ 18,134,882	$ 25,813,149

About OpGen Inc

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÃƒÅ¡M Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

CEO	Dr. Oliver Schacht Ph.D.
WEBSITE	opgen.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	85

OpGen Inc Frequently Asked Questions

What is the ticker symbol for OpGen Inc? What does OPGN stand for in stocks?

OPGN is the stock ticker symbol of OpGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OpGen Inc (OPGN)?

As of Thu Apr 18 2024, market cap of OpGen Inc is 6.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPGN stock?

You can check OPGN's fair value in chart for subscribers.

What is the fair value of OPGN stock?

You can check OPGN's fair value in chart for subscribers. The fair value of OpGen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of OpGen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is OpGen Inc a good stock to buy?

The fair value guage provides a quick view whether OPGN is over valued or under valued. Whether OpGen Inc is cheap or expensive depends on the assumptions which impact OpGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPGN.

What is OpGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, OPGN's PE ratio (Price to Earnings) is -0.24 and Price to Sales (PS) ratio is 2.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPGN PE ratio will change depending on the future growth rate expectations of investors.